Neuberger Berman Group
LGND icon

Neuberger Berman Group’s Ligand Pharmaceuticals LGND Stock Holding History

Neuberger Berman Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.5M Buy
248,355
+246,893
+16,887% +$58.2M 0.05% 408
2026
Q1 		$292K Buy
1,462
+191
+15% +$37.8K ﹤0.01% 1846
2025
Q4 		$240K Sell
1,271
-51
-4% -$9.8K ﹤0.01% 1892
2025
Q3 		$234K Buy
+1,322
New +$197K ﹤0.01% 1850
2016
Q3 		– Sell
-8,015
Closed -$596K – 1612
2016
Q2 		$596K Sell
8,015
-8,817
-52% -$654K ﹤0.01% 1211
2016
Q1 		$1.12M Buy
16,832
+3,206
+24% +$195K ﹤0.01% 1082
2015
Q4 		$922K Buy
+13,626
New +$841K ﹤0.01% 1143

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group's LGND Position: Q2 2026 in Review

Neuberger Berman Group increased its Ligand Pharmaceuticals (LGND) stake by 16,887% in Q2 2026, buying an estimated $58.2M and bringing the position to 248,355 shares worth $78.5M. The position accounts for 0.05% of the portfolio, ranked #408.

Neuberger Berman Group first reported a position in LGND in Q4 2015 and has held it in 7 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Neuberger Berman Group held 248,355 shares of Ligand Pharmaceuticals worth $78.5M as of Q2 2026.
  • Neuberger Berman Group bought 246,893 Ligand Pharmaceuticals shares in Q2 2026, an estimated $58.2M.
  • Ligand Pharmaceuticals made up 0.05% of Neuberger Berman Group's portfolio in Q2 2026, its #408 holding.
  • Neuberger Berman Group first reported a position in Ligand Pharmaceuticals in Q4 2015 and has held it in 7 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.